These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

554 related articles for article (PubMed ID: 3539322)

  • 1. Characterization of a cis-diamminedichloroplatinum(II)-resistant human ovarian cancer cell line and its use in evaluation of platinum analogues.
    Behrens BC; Hamilton TC; Masuda H; Grotzinger KR; Whang-Peng J; Louie KG; Knutsen T; McKoy WM; Young RC; Ozols RF
    Cancer Res; 1987 Jan; 47(2):414-8. PubMed ID: 3539322
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Establishment and characterization of an in vitro model of acquired resistance to cisplatin in a human testicular nonseminomatous germ cell line.
    Kelland LR; Mistry P; Abel G; Freidlos F; Loh SY; Roberts JJ; Harrap KR
    Cancer Res; 1992 Apr; 52(7):1710-6. PubMed ID: 1312897
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of carrier ligand in platinum resistance of human carcinoma cell lines.
    Schmidt W; Chaney SG
    Cancer Res; 1993 Feb; 53(4):799-805. PubMed ID: 8428361
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of a human squamous carcinoma cell line resistant to cis-diamminedichloroplatinum(II).
    Teicher BA; Holden SA; Kelley MJ; Shea TC; Cucchi CA; Rosowsky A; Henner WD; Frei E
    Cancer Res; 1987 Jan; 47(2):388-93. PubMed ID: 3539321
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanisms of resistance of human small cell lung cancer lines selected in VP-16 and cisplatin.
    Jain N; Lam YM; Pym J; Campling BG
    Cancer; 1996 May; 77(9):1797-808. PubMed ID: 8646677
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cross-resistance to diverse drugs is associated with primary cisplatin resistance in ovarian cancer cell lines.
    Hamaguchi K; Godwin AK; Yakushiji M; O'Dwyer PJ; Ozols RF; Hamilton TC
    Cancer Res; 1993 Nov; 53(21):5225-32. PubMed ID: 8106143
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multifactorial mechanisms associated with broad cross-resistance of ovarian carcinoma cells selected by cyanomorpholino doxorubicin.
    Lau DH; Lewis AD; Ehsan MN; Sikic BI
    Cancer Res; 1991 Oct; 51(19):5181-7. PubMed ID: 1717140
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biochemical pharmacology of homologous alicyclic mixed amine platinum(II) complexes in sensitive and resistant tumor cell lines.
    Yoshida M; Khokhar AR; Siddik ZH
    Cancer Res; 1994 Jul; 54(13):3468-73. PubMed ID: 8012968
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relationship of cellular glutathione to the cytotoxicity and resistance of seven platinum compounds.
    Meijer C; Mulder NH; Timmer-Bosscha H; Sluiter WJ; Meersma GJ; de Vries EG
    Cancer Res; 1992 Dec; 52(24):6885-9. PubMed ID: 1458477
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vivo model development of cisplatin-resistant and -sensitive A2780 human ovarian carcinomas.
    Rose WC; Basler GA
    In Vivo; 1990; 4(6):391-6. PubMed ID: 2103379
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sensitivity to novel platinum compounds of panels of human lung cancer cell lines with acquired and inherent resistance to cisplatin.
    Twentyman PR; Wright KA; Mistry P; Kelland LR; Murrer BA
    Cancer Res; 1992 Oct; 52(20):5674-80. PubMed ID: 1327513
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhanced replicative bypass of platinum-DNA adducts in cisplatin-resistant human ovarian carcinoma cell lines.
    Mamenta EL; Poma EE; Kaufmann WK; Delmastro DA; Grady HL; Chaney SG
    Cancer Res; 1994 Jul; 54(13):3500-5. PubMed ID: 8012973
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gene-specific repair of Pt/DNA lesions and induction of apoptosis by the oral platinum drug JM216 in three human ovarian carcinoma cell lines sensitive and resistant to cisplatin.
    O'Neill CF; Koberle B; Masters JR; Kelland LR
    Br J Cancer; 1999 Dec; 81(8):1294-303. PubMed ID: 10604725
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of a cisplatin-resistant human ovarian carcinoma cell line expressing cross-resistance to 5-fluorouracil but collateral sensitivity to methotrexate.
    Hill BT; Shellard SA; Hosking LK; Dempke WC; Fichtinger-Schepman AM; Tone T; Scanlon KJ; Whelan RD
    Cancer Res; 1992 Jun; 52(11):3110-8. PubMed ID: 1591724
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cellular pharmacology of liposomal cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexaneplatinum(II) in A2780/S and A2780/PDD cells.
    Han I; Ling YH; al-Baker S; Khokhar AR; Perez-Soler R
    Cancer Res; 1993 Oct; 53(20):4913-9. PubMed ID: 8402681
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased DNA repair as a mechanism of acquired resistance to cis-diamminedichloroplatinum (II) in human ovarian cancer cell lines.
    Masuda H; Ozols RF; Lai GM; Fojo A; Rothenberg M; Hamilton TC
    Cancer Res; 1988 Oct; 48(20):5713-6. PubMed ID: 3139281
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis and activity of a trinuclear platinum complex: [{trans-PtCl(NH3)2}2mu-{trans-Pt(3-hydroxypyridine)2(H2N(CH2)6NH2)2}]Cl4 in ovarian cancer cell lines.
    Tayyem H; Huq F; Yu JQ; Beale P; Fisher K
    ChemMedChem; 2008 Jan; 3(1):145-51. PubMed ID: 17963210
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanism-related circumvention of acquired cis-diamminedichloroplatinum(II) resistance using two pairs of human ovarian carcinoma cell lines by ammine/amine platinum(IV) dicarboxylates.
    Kelland LR; Mistry P; Abel G; Loh SY; O'Neill CF; Murrer BA; Harrap KR
    Cancer Res; 1992 Jul; 52(14):3857-64. PubMed ID: 1617660
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ormaplatin sensitivity/resistance in human ovarian cancer cells made resistant to cisplatin.
    Parker RJ; Vionnet JA; Bostick-Bruton F; Reed E
    Cancer Res; 1993 Jan; 53(2):242-7. PubMed ID: 8417816
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel mechanisms of platinum drug resistance identified in cells selected for resistance to JM118 the active metabolite of satraplatin.
    Samimi G; Kishimoto S; Manorek G; Breaux JK; Howell SB
    Cancer Chemother Pharmacol; 2007 Feb; 59(3):301-12. PubMed ID: 16770583
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.